Hematopoietic growth factors and the treatment of tumor-associated anemias

@article{Dhrsen1994HematopoieticGF,
  title={Hematopoietic growth factors and the treatment of tumor-associated anemias},
  author={Ulrich D{\"u}hrsen and Dieter Kurt Hossfeld},
  journal={Annals of Hematology},
  year={1994},
  volume={69},
  pages={213-221}
}
Erythropoietin, alone or in combination with colony-stimulating factors, is a promising agent in the treatment of patients with cancer-related ‘anemia of chronic disorders’, chemo/radiotherapy-induced anemia, or anemia due to myelodysplastic or myeloproliferative syndromes. In the first two groups, at least half of the patients can be expected to respond to erythropoietin alone, with an average response delay of about 4 weeks and maximal responses at weekly doses of approximately 1000 U/kg. In… CONTINUE READING